Volitionrx Limited (VNRX) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
VolitionRx Announces First Quarter 2015 Financial Results and Business Update
May 12, 2015 7:50 AM EDTNAMUR, Belgium, May 12, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2015.Â
First Quarter 2015 and Recent Company Highlights:
Completed NYSE MKT listing in conjunction with $10.6 million fully registered offering of common shares, plus an additional $1.5 million received in funding from a Private Placement in March... More